biostudies-literatureUnknown56Ramchandren RPharmacyclics<h4>Background</h4>This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR² regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem cell transplantation.<h4>Methods</h4>In phase 2, patients with relapsed/refractory non-germinal centre B-cell-like DLBCL received oral ibrutinib 560 mg once daily and oral lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity and intravenous rituximab 375 mg/m² on Day 1 of Cycles 1-6. The primary endpoint was overall response rate (ORR) in the response-evaluable population (received any study treatment and had ≥1 post-baseline disease assessment). ThEClinicalMedicine101779https://www.ebi.ac.uk/biostudies/studies/S-EPMC9813677biostudies-literatureThe iR² regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.PMC9813677Kassam SPing JCunningham DSzafer-Glusman EJohnson PMorgan DJohnson RRamchandren RGoy AVerhoef GEckert KRuan JMunoz JGhosh NRadford JOffner Fde Vos SBailly SFayad LNeuenburg JKArdeshna KMfalseThe iR² regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.<h4>Background</h4>This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR² regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem cell transplantation.<h4>Methods</h4>In phase 2, patients with relapsed/refractory non-germinal centre B-cell-like DLBCL received oral ibrutinib 560 mg once daily and oral lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity and intravenous rituximab 375 mg/m² on Day 1 of Cycles 1-6. The primary endpoint was overall response rate (ORR) in the response-evaluable population (received any study treatment and had ≥1 post-baseline disease assessment). Th2023-01-01T00:00:00Z2023 Feb2026-07-14T21:08:42.139Z2025-04-06T00:51:15.391ZS-EPMC98136773661890010.1016/j.eclinm.2022.101779